US › Healthcare

Nkarta Inc (NKTX)

US · Healthcare · Biotechnology

$2.26+5.12%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-27.8M
Profit YoY
+13.0%
EPS
$-0.37
EPS estimate
$-0.36

EPS came in at -0.37 against a street estimate of -0.36 — a miss of 2.7%.

Key statistics

Market cap
$149.5M
Forward P/E
0.0
P/B
0.52
Book value
$4.01
EPS (TTM)
$-1.35
52-week high
$3.72
52-week low
$1.70
50-day MA
$2.77
200-day MA
$2.39
Beta
0.92

Analyst view

Analysts rate Nkarta Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $11.33.

Shareholding

Insiders
4.88%
Institutions
80.84%

Largest institutional holders

FundStake
RA Capital Management, LLC15.10%
BlackRock Inc6.30%
NEA Management Company, LLC4.99%
Samsara BioCapital, LLC4.90%
SR ONE CAPITAL MANAGEMENT, LP4.66%
GSK PLC4.40%
Monaco Asset Management3.52%
Alyeska Investment Group, L.P.2.91%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nkarta Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.